Necessity of Utilizing Physiological Glucocorticoids for Managing Familial Mediterranean Fever.
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
23 Mar 2020
23 Mar 2020
Historique:
entrez:
24
3
2020
pubmed:
24
3
2020
medline:
6
1
2021
Statut:
epublish
Résumé
BACKGROUND Familial Mediterranean fever is an auto-inflammatory disease caused by pyrin mutations. Glucocorticoids inhibit the production and secretion of inflammatory cytokines, including IL-6 and IL-1ß, from inflammatory cells and suppress the activation of nuclear factor-kappaB in the nucleus. However, the functions of physiological glucocorticoids in the disease remain unknown. CASE REPORT We report the case of a Japanese man with familial Mediterranean fever complicated by isolated adrenocorticotropic hormone deficiency. Patient non-compliance with hydrocortisone replacement therapy led to a series of pericarditis and fever episodes. Subsequently, the regular administration of colchicine alone could not prevent auto-inflammation. The clinical course of treatment suggested that the absence of physiological levels of glucocorticoids is crucial for familial Mediterranean fever attacks. Because familial Mediterranean fever is a pyrin abnormality-induced auto-inflammatory disease that subsequently activates cytokines via the nucleotide-binding domain, leucine-rich repeat/pyrin domain-containing 3 inflammasomes and the absence of glucocorticoids can exacerbate the severity of the auto-inflammatory disease. CONCLUSIONS Physiological glucocorticoid levels appear to be essential for the regulation of inflammasome activation via IL-6-negative regulation. However, pharmacological levels of glucocorticoids are not currently used for the prevention of familial Mediterranean fever attacks. Physicians should be aware of adrenal insufficiency as a possible disorder when they encounter cases of refractory familial Mediterranean fever.
Identifiants
pubmed: 32203056
pii: 920983
doi: 10.12659/AJCR.920983
pmc: PMC7117857
doi:
Substances chimiques
Cytokines
0
Glucocorticoids
0
Inflammasomes
0
Colchicine
SML2Y3J35T
Hydrocortisone
WI4X0X7BPJ
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
e920983Références
Nat Rev Immunol. 2017 Apr;17(4):233-247
pubmed: 28192415
J Clin Invest. 2017 Apr 3;127(4):1136-1145
pubmed: 28319043
Arthritis Rheum. 2009 Jun;60(6):1851-61
pubmed: 19479870
Clin Exp Rheumatol. 2002 Jul-Aug;20(4 Suppl 26):S8-12
pubmed: 12371641
Eur J Rheumatol. 2014 Mar;1(1):21-33
pubmed: 27708867
Arthritis Res Ther. 2016 Jul 30;18:175
pubmed: 27473114
Am J Med. 1964 Jun;36:893-918
pubmed: 14162896
Front Immunol. 2017 Mar 23;8:253
pubmed: 28386255
Ther Adv Endocrinol Metab. 2019 Feb 02;10:2042018818821294
pubmed: 30746120
Front Immunol. 2019 Aug 07;10:1745
pubmed: 31456795
J Rheumatol. 1998 Aug;25(8):1508-14
pubmed: 9712092
Orphanet J Rare Dis. 2019 Oct 15;14(1):224
pubmed: 31615541
J Clin Endocrinol Metab. 2016 Feb;101(2):364-89
pubmed: 26760044
Clin Exp Rheumatol. 2000 Nov-Dec;18(6):655-8
pubmed: 11138324